Phagenesis appoints chairman and ceo

Will lead the development of treatments for stroke victims

Phagenesis, a UK leader in technology for the treatment of stroke patients, has appointed Henry Hyde-Thomson as chairman and Daniel Green as chief executive. They will lead the University of Manchester spin out in the development of a new class of treatments for stroke victims suffering from dysphagia, a condition that prevents or impairs the safe swallowing of food and drink.

Phagenesis’ technology is a device that delivers electrical pulses to the throat region that can ‘awaken’ the brain to help restore swallowing function. At least 50% of stroke victims have impaired swallowing. Apart from a severe reduction in quality of life, dysphagia often leads to the inhalation of liquids and the development of life-threatening pneumonia.

Green was formerly chief executive of Repregen, an Imperial College spinout. Before that, he was a venture capital investor at HBM Partners in Zurich, Switzerland, Dresdner Kleinwort and MVM, in London, UK.

You may also like

Research & Development

Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform

Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Manufacturing

L.B. Bohle hosts successful continuous manufacturing workshop in Brazil

Focus on continuous wet granulation and drying for research, development and small-scale production
Manufacturing

Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development

Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
Research & Development

Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption

A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
Manufacturing

Degasser for volatile and aggressive solvents

Biotech Fluidics announce the DEGASi Integration HFIP - a high-performance online system designed to efficiently degas even the toughest solvents. This unique degasser is fully compatible with a wide range of volatile and aggressive liquids including Hexafluoroisopropanol (HFIP) and silanes but can also manage all other solvents used for GPC/SEC and HPLC
Research & Development

Symeres joins forces with Ambagon Therapeutics to expand molecular glue research in colorectal cancer

The pair will aim to explore a new class of small molecules, known as molecular glues, for potential therapeutic use in colorectal cancer and other hard-to-target diseases as an alternative to traditional therapies
Research & Development

University of Exeter leads £4.5m Wellcome-funded initiative to develop bioimaging tools for fungal pathogens

An international collaboration spanning the universities of Exeter, Edinburgh and Cape Town has secured £4.5m to develop specialist bioimaging tools for WHO-priority fungal pathogens
Subscribe now